IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.212
NA - Nord America 1.895
EU - Europa 727
SA - Sud America 463
AF - Africa 48
OC - Oceania 25
Totale 12.370
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 7.162
US - Stati Uniti d'America 1.813
CN - Cina 937
HK - Hong Kong 681
BR - Brasile 340
VN - Vietnam 232
GB - Regno Unito 192
IT - Italia 178
DE - Germania 112
IN - India 54
AR - Argentina 47
CA - Canada 47
FI - Finlandia 42
NL - Olanda 36
ID - Indonesia 31
CZ - Repubblica Ceca 28
EC - Ecuador 28
MX - Messico 25
PL - Polonia 25
AU - Australia 24
TR - Turchia 23
UA - Ucraina 22
ZA - Sudafrica 22
FR - Francia 21
JP - Giappone 18
BD - Bangladesh 17
ES - Italia 17
PY - Paraguay 13
CL - Cile 9
CO - Colombia 9
RU - Federazione Russa 9
SE - Svezia 9
CH - Svizzera 6
VE - Venezuela 6
MA - Marocco 5
PE - Perù 5
ET - Etiopia 4
LB - Libano 4
PK - Pakistan 4
SA - Arabia Saudita 4
UY - Uruguay 4
UZ - Uzbekistan 4
AT - Austria 3
BE - Belgio 3
BG - Bulgaria 3
BY - Bielorussia 3
DZ - Algeria 3
EG - Egitto 3
IQ - Iraq 3
IR - Iran 3
KR - Corea 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MY - Malesia 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
IL - Israele 2
IS - Islanda 2
JM - Giamaica 2
JO - Giordania 2
LT - Lituania 2
PA - Panama 2
RO - Romania 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TL - Timor Orientale 2
AM - Armenia 1
AO - Angola 1
BJ - Benin 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
GH - Ghana 1
GN - Guinea 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
KE - Kenya 1
KH - Cambogia 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
ML - Mali 1
MU - Mauritius 1
NP - Nepal 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SV - El Salvador 1
Totale 12.369
Salva come PNG Salva come JPEG
Città #
Hong Kong 672
Singapore 658
Ashburn 485
Hefei 391
Boardman 217
Beijing 182
Dallas 179
London 155
Shanghai 134
San Jose 127
Ho Chi Minh City 84
Rome 76
Los Angeles 62
Munich 62
Council Bluffs 60
San Francisco 46
Hanoi 41
São Paulo 40
Seattle 31
Brno 28
Santa Clara 28
New York 27
Turku 27
Pune 26
Warsaw 22
West Jordan 22
Amsterdam 21
Guangzhou 20
Toronto 20
Mexico City 17
Tokyo 17
Washington 17
Rio de Janeiro 16
Helsinki 15
Montreal 15
Boston 14
Da Nang 13
Guayaquil 13
Canberra 12
Haiphong 12
Sona 11
Johannesburg 10
Chennai 9
Stockholm 9
Brasília 8
Brooklyn 8
Atlanta 7
Chicago 7
Hải Dương 7
Manchester 7
Melbourne 7
Paris 7
Shenzhen 7
Charlotte 6
Quito 6
Redmond 6
Thái Bình 6
Thái Nguyên 6
Biên Hòa 5
Curitiba 5
Milan 5
Secaucus 5
Sydney 5
Zhengzhou 5
Ankara 4
Belo Horizonte 4
Buenos Aires 4
Can Tho 4
Central 4
Frankfurt am Main 4
Houston 4
Jakarta 4
Kyiv 4
Lima 4
Montes Claros 4
Naples 4
Oklahoma City 4
Phoenix 4
Shijiazhuang 4
The Dalles 4
Addis Ababa 3
Asunción 3
Bari 3
Belém 3
Bogotá 3
Bologna 3
Boydton 3
Brownsville 3
Buffalo 3
Bắc Giang 3
Cachoeirinha 3
Camden 3
Campinas 3
Carapicuíba 3
Delhi 3
Denver 3
Florianópolis 3
Guarulhos 3
Haikou 3
Hangzhou 3
Totale 4.392
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 230
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 214
Advances in management of periprosthetic joint infections: an historical prospective study 213
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 212
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 208
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 208
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 207
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 204
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 203
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 200
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 197
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 197
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 196
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 196
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 196
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 194
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 193
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 192
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 189
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 188
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 186
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 185
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 185
Assessment of liver function by the exhaled breath-print during chronic liver disease 184
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 183
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 139
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 117
GH-resistance in different stages of chronic liver disease 114
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 110
Diabetes in chronic liver disease: from old concepts to new evidence 110
[A 73-year-old woman with vomiting and metabolic alkalosis] 108
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 104
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 104
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 103
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 100
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 99
A challenging alfa-fetoprotein in a cirrhotic patient 97
[A 61-year-old woman with abdominal pain and urination disorders] 97
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 96
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 96
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 96
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 93
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 92
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 91
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 91
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 88
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 87
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 87
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 85
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 83
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 83
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 78
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 78
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 76
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 75
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 75
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 72
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 69
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 68
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 63
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 55
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 51
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 50
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 50
Pain and Frailty in Hospitalized Older Adults 49
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 47
Reelin expression in human liver of patients with chronic hepatitis C infection 46
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 46
Identification of matrix metalloprotease 10 (mmp10) as a key new mediator of the regenerative response of the liver 45
TNF-alpha and growth hormone resistance in patients with chronic liver disease 44
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 44
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 43
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 43
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 42
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 40
Identification of Fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure 40
What changed in the Italian internal medicine and geriatric wards during the lockdown 40
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 39
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 39
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 38
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 38
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver inury 38
Portal and interface chronic inflammation are associated with the progenitor cell compartment activation during NAFLD 38
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 38
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 37
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis 37
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 37
Hepatic complications of bariatric surgery : the reverse side of the coin 37
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 37
Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma 37
Multimorbidity and polypharmacy in the elderly: lessons from REPOSI 37
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 37
Matrix metalloproteinase-10 contributes to hepatocellular carcinoma development in a novel crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis 37
Interplay between SIRT-3, metabolism and its tumor suppressor role in hepatocellular carcinoma 37
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 37
MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION 36
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver injury 36
Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis 36
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease 35
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population 35
Totale 9.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20262.982 620 332 457 810 255 354 154 0 0 0 0 0
Totale 12.447